florida CLIA logo

AKESOgen receives State of Florida Licensure to offer Clinical Testing

Atlanta, GA –June 30th, 2015– Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has received the Florida Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of Florida.

The Georgia based company said in a statement that it believes its cytogenomics tests for a wide spectrum of solid and liquid tumors will be of particular benefit to the state –as the test is offered as a complement to NGS clinical oncology testing.

“This endorsement by the State of Florida for AKESOgen provide our comprehensive oncology tests and services gives AKESOgen access to the single largest US oncology diagnostics market, and will help accelerate our commercial growth in this sector.” said Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.

AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

CSO of AKESOgen to speak at and attend the Third International Conference on Biomarkers Discovery and Clinical Application.

AKESOgen scientists to attend the third ICB conference in Shanghai, China from October 17-18, 2015.  AKESOgen’s CSO, Mark Bouzyk, has been invited to speak as a leading expert on genomic profiling in multiple cancers, specifically towards Precision Medicine.

ICB logo-Shanghai           AKESOgen-Logo333

Please email info@akesogen.com or call 770 542 0890 if you want to schedule an appointment with a delegate or to discuss your genomics needs.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen to host and sponsor Industry tour on behalf of Georgia Bio

Please join Georgia Bio’s Emerging Leaders Network on their Industry Tour for an inside look of AKESOgen, a premier provider of genetic analysis.

This industry tour will provide participants an inside look of AKESOgen, a leader in personalized medicine and genomics.  Equipped with industry experts, AKESOgen provides high quality genomic analysis services, performing over 21,000 whole genome genotyping monthly. It is the only facility in the United States that has developed and performs clinical commercial copy number alteration (CNA) microarray analysis for formalin-fixed, paraffin-embedded (FFPE) tissue samples on Illumina platforms. AKESOgen provides contract research, clinical diagnostic and clinical trial services to pharmaceutical, biotech, academic, and government research institutions.  The company supported over 100 academic investigators in 2014.

All participants should be dressed smart casual with closed toe shoes.

To register for this event and further details please go to: http://www.gabio.org/events/event_details.asp?id=600212

When:
Wednesday, September 09, 2015
10:30 am – 12:30 pm

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
20150623_132544

AKESOgen at Festival of Genomics

AKESOgen scientists attended and spoke at Front Line Genomics’ first inaugural Festival of Genomics Convention in Boston, MA, June 22-24, 2015. Please email info@akesogen.com or call 770 542 0890 if you want to schedule an appointment with a delegate or to discuss your genomics needs.

AKESOgen-Logo333frontline genomics

 

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail